Evidence map›Paper›PMID 42539481›Full record

ArticleReviews in cardiovascular medicine2026

Correction: Amr et al. Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort. Reviews in Cardiovascular Medicine. 2024; 25(6): 225.

Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Ali AmrInstitute for Cardiomyopathies & Center for Cardiogenetics, Department of Medicine III, University of Heidelberg, 69120 Heidelberg, Germany.
Elham KayvanpourInstitute for Cardiomyopathies & Center for Cardiogenetics, Department of Medicine III, University of Heidelberg, 69120 Heidelberg, Germany.
Christoph ReichInstitute for Cardiomyopathies & Center for Cardiogenetics, Department of Medicine III, University of Heidelberg, 69120 Heidelberg, Germany.
Jan KoelemenInstitute for Cardiomyopathies & Center for Cardiogenetics, Department of Medicine III, University of Heidelberg, 69120 Heidelberg, Germany.
Shamily AsokanInstitute for Cardiomyopathies & Center for Cardiogenetics, Department of Medicine III, University of Heidelberg, 69120 Heidelberg, Germany.
Norbert FreyInstitute for Cardiomyopathies & Center for Cardiogenetics, Department of Medicine III, University of Heidelberg, 69120 Heidelberg, Germany.
Benjamin MederInstitute for Cardiomyopathies & Center for Cardiogenetics, Department of Medicine III, University of Heidelberg, 69120 Heidelberg, Germany.
Farbod Sedaghat-HamedaniInstitute for Cardiomyopathies & Center for Cardiogenetics, Department of Medicine III, University of Heidelberg, 69120 Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.31083/j.rcm2506225.].

Identifiers

PMID42539481
PMCPMC13423721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.